<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927004</url>
  </required_header>
  <id_info>
    <org_study_id>Moss IISP#36409</org_study_id>
    <secondary_id>3144 Wright-Merck</secondary_id>
    <secondary_id>HR47-2009</secondary_id>
    <nct_id>NCT00927004</nct_id>
  </id_info>
  <brief_title>Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis</brief_title>
  <official_title>A Randomised Placebo-controlled Trail of Mechanical and Cold Hyperalgesia in Subjects With Painful Knee Osteoarthritis, Compared With Matched Controls, &amp; Whether This Hyperalgesia Can be Modified by a 2-week Course of Etoricoxib 60mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curtin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Curtin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to better understand the way in which painful osteoarthritis affects
      different people and whether an anti-inflammatory medication such as Arcoxia (etoricoxib) can
      help to modify this pain. The study will use questionnaires and tests of pain sensitivity to
      identify arthritis sufferers with more widespread, nerve-type pain and then to investigate
      whether a daily dose of Arcoxia is more effective than a placebo pill in reducing these
      symptoms and improving functional movements. The study will also be comparing the same test
      results of a small group of subjects without knee pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pressure Pain Threshold</measure>
    <time_frame>15 days, 3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster University Osteoarthritis Index (knee) - pain subscale</measure>
    <time_frame>15 days, 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cold Pain Threshold</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topical Cold Response</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Measure (aggregated locomotor score, sit-to-stand time)</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC (knee) total</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Quality Assessment Scale</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PainDETECT questionnaire</measure>
    <time_frame>15 days, 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Etoricoxib 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib (Arcoxia)</intervention_name>
    <description>60 mg, daily dose, oral delivery, 14 days duration</description>
    <arm_group_label>Etoricoxib 60 mg</arm_group_label>
    <other_name>Arcoxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Daily dose (1 pill), oral delivery, 14 days</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unilateral diagnosis of Knee OA &gt; 6 months

          -  knee pain &gt; 4/10 on WOMAC pain subscale

          -  if pain in contralateral knee, no greater than &quot;mild&quot;

          -  no other significant joint involvement

          -  ARA functional Class I, II or III

          -  no arthroscopy or injections into index knee in last 6 months

        Exclusion Criteria:

          -  history of systemic inflammatory or chronic pain disorders (especially fibromyalgia)

          -  neurological deficit

          -  recent (&lt; 6 months) lower limb surgery

          -  allergic reaction to NSAIDs or aspirin

          -  skin allergies, dermatitis

          -  contraindications to Cox-2 inhibitors:

               -  congestive heart failure (NYHA II-IV)

               -  unstable hypertension

               -  ischaemic heart disease

               -  peripheral artery disease

               -  cerebrovascular disease including CABG or angioplasty within 1 year

          -  severe hepatic dysfunction

          -  active GI bleeding or peptic ulceration

          -  reduced creatinine clearance &lt; 30 mL/min

          -  current use of high dose (&gt; 325 mg daily) aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Wright, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Curtin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://physiotherapy.curtin.edu.au</url>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Curtin University</investigator_affiliation>
    <investigator_full_name>Penny Moss</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>mechanical hyperalgesia</keyword>
  <keyword>cold hyperalgesia</keyword>
  <keyword>chronic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

